At a glance
- Originator GlaxoSmithKline
- Class Anti-inflammatories; Antipruritics
- Mechanism of Action Leukotriene B4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 21 Jul 1995 No-Development-Reported for Inflammation in United Kingdom (unspecified route)